PODESTA GROUP, INC. for GENZYME
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Prescription Drug User Fee Act reauthorization. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). Product exclusivity issues.
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi-aventis has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRISTINA ANTELO | — |
| SHARON COHEN | — |
Health Issues HCR
340B issues Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi-aventis has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRISTINA ANTELO | — |
| SHARON COHEN | — |
Medicare/Medicaid MMM
H. Con. Res 112, Establishing the budget for the US Government for FY 2013. Medicare issues related to end stage renal disease. Medicare reimbursement issues. ASP changes; 340B issues.
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi-aventis has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRISTINA ANTELO | — |
| SHARON COHEN | — |
| ANTHONY PODESTA | — |
Budget/Appropriations BUD
FY 2013 budget appropriations. H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi-aventis has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRISTINA ANTELO | — |
| SHARON COHEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.